Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)

Sonnet BioTherapeutics shares are trading lower by 15.5% Wednesday afternoon. The company announced a 1-for-8 reverse stock split.

SONN stock results show that Sonnet BioTherapeutics beat analyst estimates for earnings per share the third quarter of 2024.

SONN stock results show that Sonnet BioTherapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 8.5% to $1.18 Thursday morning on downward momentum.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% to 33,025.71 while the NASDAQ fell 2.45% to 12,817.76. The S&P 500 also fell, dropping, 1.48% to 4,184.98.

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ.